OPME denials: why they happen and how to prevent them

OPME (implants and special materials) is the highest-unit-value item on surgical claims and, for that reason, the one that receives the most scrutiny from payers’ auditors. But an OPME denial rarely questions whether the material was actually implanted. It questions whether there is documentation proving its use, whether the authorization covers exactly the material billed and whether traceability is formally recorded in the medical record. In most cases, the difference between a denied implant and a paid implant lies in the quality of the record, not the quality of the procedure.

This denial profile has a direct practical implication: most OPME denials are preventable. They do not require clinical changes, do not depend on contract renegotiation and are not subject to judgments of medical appropriateness. They depend on process, traceability and documentation compliance, three elements the hospital controls entirely.

Why OPME accounts for so many denials

The high unit value of OPME is the first factor. An orthopedic implant, a cardiovascular prosthesis or a spinal fixation system can represent tens or hundreds of thousands of reais on a single claim. From the payer’s point of view, that value justifies a more rigorous documentation review than the one applied to commonly used materials. For more on the financial impact of OPME, see OPME: the impact of these materials on hospital costs.

The second factor is the multiplicity of documentation requirements. To bill for an OPME item, the hospital must simultaneously have the payer’s prior authorization, the traceability label in the medical record, the invoice linked to the material, the entry in the surgical description and a match between the material billed and the material authorized. These are five independent elements, each with its own owner in the hospital process. When any one of them is missing, the denial happens.

The third factor is how the process is spread across different areas. Authorization is the responsibility of billing. Traceability is the responsibility of the surgical team. The invoice is the responsibility of the storeroom. The entry in the surgical description is the responsibility of the physician.

The main causes of OPME denials

Traceability label missing from the medical record

Anvisa (National Health Surveillance Agency) RDC No. 14/2011 requires every implantable material to have a traceability label, with one copy mandatorily attached to the clinical record. This label identifies the product, the manufacturer, the lot and the serial number of the implant. Without it in the medical record, the payer has no formal proof of which specific material was used, and it denies the item regardless of whether the invoice is present.

Material billed differs from material authorized

The payer’s prior authorization specifies the material to be used: code, description and, in some cases, manufacturer and model. When the material actually implanted differs from the one authorized, whether because of a substitution during surgery or an entry error in billing, the payer denies it for not matching the authorization in force. This denial has formal grounds and a low reversal rate without a new authorization covering the material used.

Invoice missing or not linked to the item

Each OPME item billed on the claim must have a corresponding invoice identifying the material, manufacturer, quantity and unit price. A missing invoice, or one not linked to the item in the claim documentation, is direct grounds for a denial, even if the traceability label is in the medical record.

Material substitution without notifying the payer

OPME substitutions during surgery, whether because the authorized material is unavailable or because of the surgeon’s clinical decision, must be reported to the payer before billing. A substitute material billed without notice and without a new authorization is denied on formal grounds, even when it is clinically equivalent to the original.

Quantity billed differs from quantity recorded

The quantity of OPME billed must match exactly what was recorded in the surgical description and in the operating room’s consumption record. Quantity discrepancies lead to technical denials due to inconsistency between the charge and the care record.

Material not recorded in the surgical description

The Ministry of Health’s Manual of Good Practices in OPME Management requires the responsible professional to record in the surgical description all information about each material used: name, manufacturer, size, quantity and a description of the implant performed. When an item is billed but does not appear in the surgical description, the payer has no care evidence of its use and denies it for lack of a record.

What regulation protects and what it does not

CFM (Federal Council of Medicine) Resolution No. 2,448/2025 establishes significant protection for the provider hospital: the payer’s physician auditor is prohibited from denying OPME that was previously authorized and proven to have been used. The rule also prohibits using payers’ accreditation programs as grounds for denying OPME coverage.

This protection, however, has a precise limit: it applies to the clinical merit of the indication, not to documentation failures. The payer cannot question the indication for the prosthesis when there was prior authorization and the procedure was proven to have been performed. But it can deny for lack of traceability, for a mismatch between the material billed and the material authorized or for a missing invoice. In these cases, the denial is not a dispute on the merits but a process failure, and the resolution’s protection does not apply.

A hospital that documents correctly has explicit regulatory protection against denials on the merits. A hospital with incomplete documentation loses that protection, even when the procedure was technically correct and clinically indicated.

How to prevent OPME denials

Preventing OPME denials happens at three points in the process, each with a specific owner and criterion.

In the operating room, during the procedure: the traceability label must be attached to the medical record at the time of implantation, and the surgical description must include all the information required by the Ministry of Health’s Manual of Good Practices. Any material substitution must be recorded immediately, identifying the material used and the clinical justification.

In billing, before submission: the claim must be checked by cross-referencing the prior authorization with the material billed, the surgical description with the quantity entered and the invoice with the corresponding item. This check must be systematic and documented, without depending on the individual attention of whoever closes the claim.

In prospective auditing, as a formal process: the review of claims with OPME before submission must cover traceability, compliance with the authorization, invoice linkage and the entry in the surgical description. In hospitals with a high volume of surgeries, automating this check is what ensures 100% coverage of claims without increasing the team’s workload.

Documented OPME is not denied

OPME denials are preventable in most cases. They do not depend on renegotiating the contract with the payer, do not require changes to clinical protocols and are not subject to judgments of medical appropriateness. They depend on process: traceability formally recorded at the time of implantation, compliance with the authorization verified before billing, complete documentation before submission.

Rivio automatically audits claims with OPME before they are submitted to the payer, checking traceability, compliance with the authorization, invoice linkage and the entry in the surgical description. By contract, Rivio commits to reimbursing the hospital 100% if the denial is not reversed.

Frequently asked questions about OPME denials

What is an OPME denial?

An OPME denial is the health plan’s full or partial refusal to pay for an implantable material billed on the hospital claim. It occurs mainly because of a missing traceability label in the medical record, a mismatch between the material billed and the material authorized, a missing invoice or one not linked to the item, and material not recorded in the surgical description.

Why is the traceability label mandatory?

Anvisa RDC No. 14/2011 requires every implantable material to be accompanied by a traceability label, with one copy mandatorily attached to the clinical record. Without this label, the payer has no formal proof of which specific material was used and may deny the item regardless of whether the invoice is present.

Can preauthorized material be denied?

CFM Resolution No. 2,448/2025 prohibits the physician auditor from denying OPME that was previously authorized and proven to have been used. This protection applies to the clinical merit of the indication. The regulatory protection exists, but it presupposes adequate documentation: the payer can still deny for documentation failures, such as missing traceability, a mismatch between the material billed and the material authorized or a missing invoice.

How do you appeal an OPME denial?

The strategy depends on the cause. Denials for missing traceability are hard to reverse without the original document. Denials for not matching the authorization can be reversed by presenting a new authorization covering the material used, when available. Denials for a missing invoice are reversed by presenting the corresponding tax document. In all cases, the appeal must be filed within the contractual deadline.